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Abstract
Mesenchymal stem cells (MSC) are promising for cell-based regeneration therapies but up to date it is still controversial
whether their function is maintained throughout ageing. Aim of this study was to address whether frequency, activation in
vitro, replicative function, and in vitro lineage choice of MSC is maintained throughout ageing to answer the question
whether MSC-based regeneration strategies should be restricted to younger individuals. MSC from bone marrow aspirates
of 28 donors (5–80 years) were characterized regarding colony-forming unit-fibroblast (CFU-F) numbers, single cell cloning
efficiency (SSCE), osteogenic, adipogenic and chondrogenic differentiation capacity in vitro. Alkaline phosphatase (ALP)
activity, mineralization, Oil Red O content, proteoglycan- and collagen type II deposition were quantified. While CFU-F
frequency was maintained, SSCE and early proliferation rate decreased significantly with advanced donor age. MSC with
higher proliferation rate before start of induction showed stronger osteogenic, adipogenic and chondrogenic
differentiation. MSC with high osteogenic capacity underwent better chondrogenesis and showed a trend to better
adipogenesis. Lineage choice was, however, unaltered with age. Conclusion: Ageing influenced activation from dormancy
and replicative function of MSC in a way that it may be more demanding to mobilize MSC to fast cell growth at advanced
age. Since fast proliferation came along with high multilineage capacity, the proliferation status of expanded MSC rather
than donor age may provide an argument to restrict MSC-based therapies to certain individuals.
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Introduction
Tissue-specific regenerative cells like adult stem cells are thought
to be required for tissue replacement throughout human lifespan.
They are characterized by their capacity to self-renew and a
multilineage differentiation potential which allows them on
demand to yield different cells of a tissue. Stem cells are thought
to be largely retained in a quiescent stage over prolonged periods
of dormancy in the body, but can be stimulated to enter the cell
cycle to produce different effector cells through subsequent rounds
of proliferation. A hierarchical differentiation permits the
production of large numbers of differentiated cells from a single
stem cell and balances the need for high cell numbers with the
protection of stem cells from mutagenesis and replicative
exhaustion.
Evident aspects of human ageing like progressive decrease in
bone mass, replacement of bone marrow by fat marrow, chronic
degeneration of articular cartilage and intervertebral disc tissue
and delayed fracture healing [1–3] may result from an age-
associated decline in either the number or the replicative function
of mesenchymal regenerative cells – adult mesenchymal stem cells
(MSC). In addition, activation of MSC from dormancy into the
cell cycle in response to extracellular cues and their lineage choice
to undergo differentiation in a repair situation may change with
increasing age. This leads to the question whether the proper
physiological function of MSC will be maintained throughout life.
MSC can easily be isolated from bone marrow and other tissues
[4–8] and their multipotency and high self-renewing capacity
combined with immunomodulatory properties favour them as an
attractive cell source for clinical applications in immunological
disorders, heart diseases or after musculoskeletal injury.
Due to their low number in primary isolates [9] it is usually
necessary to culture and expand MSC in vitro before clinical use.
Expanded MSC are a heterogeneous cell population influenced by
a lot of extrinsic factors that might change their properties [10–
13]. In this context the question arises whether donor age might be
one factor influencing the frequency and characteristics of MSC in
a way that MSC-based therapies should be restricted to a certain
age group. Existing studies which are engaged with this question
often illustrate only one [14–19] or two parameters [20–25],
mostly proliferation and in vitro osteogenesis of MSC. Although all
studies work with MSC coaxed back into the cell cycle in vitro, the
in vitro reactivation of single MSC from in vivo dormancy was so
far not addressed in the context of ageing. Single cell cloning
efficiency (SSCE) of minimally expanded MSC populations can
provide important information about the ease and quality by
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study addressing SSCE of MSC in the context of ageing.
Many studies interested in age-related changes determined the
frequency of MSC in the mononuclear cell fraction of bone
marrow aspirates and reported no correlation with donor age
[20,21,23,26,27] or a decline in older donors [28,29]. Proliferation
rate during culture expansion decreased with age according to
some authors [15,22,24,25,29] but not by others [14,19]. Age-
related changes in MSC may, however, also include a loss or
reduction of differentiation potential to a selected lineage thus
changing lineage commitment of MSC into one or two preferred
directions over others. Surprisingly, questions of MSC lineage
choice have so far not been addressed in the context of ageing. For
single lineages, an unaltered differentiation capacity with age was
reported for adipogenesis [21,22,29,30] and chondrogenesis
[23,29,30]. For osteogenesis, reports on maintained differentiation
capacity [18,20,21,25,26,30] contrasted others about a declining
osteogenesis with age [24,29,31].
In light of conflicting data and limitations in study design of
current literature, a comprehensive study delivering a broad
spectrum of age-related aspects in one study on a high number of
donors with a broad age range was needed. In order to draw a well
funded conclusion on an age-related maintenance of physiological
function ofhuman MSCinvitro,this study addressed eight different
parameters, including MSC frequency, activation, replicative
function and in vitro lineage commitment. We determined the
number of CFU-F per mononuclear cell fraction, the SSCE of
minimally expanded MSC, the proliferation rate at different
passages, and quantified one or two parameters per lineage for
osteogenic, adipogenic and chondrogenic differentiation. This
allowed us further to address a possible interdependence between
growth properties and differentiation and between osteogenesis,
adipogenesis and chondrogenesis of MSC. In context with a critical
review of the available literature, this so far most comprehensive
study provides a sound basis to decide whether MSC-based
regeneration strategies should be restricted to a certain age group.
Materials and Methods
Isolation of MSC
MCS from 28 donors were isolated from fresh bone marrow.
Aspirates were harvested from femur shaft of patients undergoing
total hip replacement (donors above 20 years) or from iliac crest
from patients undergoing osteotomy (donors below 20 years). All
donors above 60 years as well as six of eight donors from the
middle aged group underwent implant surgery due to hip
osteoarthritis. The study was approved by the local ethics
committee (medical faculty of Heidelberg) and written consent
was obtained from all individuals included in the study. The age of
the patients (14 male and 14 female) ranged from 5 to 80 years
(mean 40.4626.6 years). Cells were fractionated by Ficoll density
centrifugation and the mononuclear cell fraction was seeded into
culture flasks at a density of 5610
5 cells per cm
2 in expansion
medium [32,33] composed of DMEM high glucose (Gibco,
Invitrogen, Karlsruhe, Germany), 2% fetal calf serum (FCS)
(Seromed/Biochrom, Berlin, Germany), 40% MCDB201,
2610
28 M dexamethasone, 10
24 M ascorbic acid 2-phosphate,
2% ITS supplement (all Sigma, Deisenhofen, Germany), 100
units/ml penicillin and 100 mg/ml streptomycin (Biochrom AG,
Berlin, Germany), 10 ng/ml recombinant human epidermal
growth factor (Miltenyi, Bergisch Gladbach, Germany) and
recombinant human platelet-derived growth factor BB (Active
Bioscience, Hamburg, Germany) and maintained at 37uCi na
humidified atmosphere and 6% CO2. After 24 hours the cells
were washed with phosphate-buffered saline (PBS) to remove non-
adherent cells and MSC were expanded as indicated.
Colony-forming unit-fibroblasts
Seven days after standardized seeding at 5610
5 mononuclear
cells per cm
2, colony-forming unit-fibroblasts (CFU-F) were
counted in a T25 culture flask under the microscope. Cell clusters
of more than 30 cells were defined as one CFU-F originating from
one clonal cell.
Single cell cloning efficiency
After 6–8 days of culture, cells from passage 0 were harvested
using trypsin/EDTA and reseeded in expansion medium into two
96-well culture plates per donor at a statistical density of one cell
per well. After additional 14 days of culture with medium changes
3 times a week, wells which reached 30 or more cells per well were
counted as single cell clones.
MSC expansion and determination of generation time
MSC were passaged by re-seeding at 5000 cells/cm
2 in a T25
culture flask with expansion medium and medium changes three
times a week. At 80% confluency the cells were separated with
trypsin/EDTA and re-seeded at the same density as long as the
isolate allowed. At each passage the generation time (G) was
determined by the formula: G=(log26T)/(logY2logX) with
T=time in culture per passage [hours], Y=number of cells at
the end of passage, X=number of cells at seeding.
Induction of Osteogenesis
MSC from passage 3 were harvested with trypsin/EDTA and
18,420 MSC/cm
2 (35,000 cells per well) were seeded in osteogenic
induction medium consisting of DMEM high glucose (Gibco,
Invitrogen, Karlsruhe, Germany), 10% FCS (Biochrom, Berlin,
Germany), 0.1 mm dexamethasone, 0.17 mM ascorbic acid 2-
phosphate, 10 mM b-glycerophosphate (all Sigma, Deisenhofen,
Germany) and 100 units/ml penicillin, 100 mg/ml streptomycin
(Biochrom, Berlin, Germany).
At day 21 osteogenesis was quantified by alkaline phosphatase
assay. In brief, monolayer cells were lysed in 0.5 ml 1% Triton X-
100 (Sigma, Deisenhofen, Germany). 100 ml lysate were incubated
with 100 ml of 1 mg/ml p-nitrophenylphosphate in ALP-buffer
(0.1 M glycine, 1 mM MgCl2, 1 mM ZnCl2, pH 10.4) and the
substrate turnover was measured at 405/490 nm using an ELISA
reader MRX (Dynatech Laboratories, Stuttgart, Germany).
Results were standardized to whole protein content of the lysates
measured with Micro BCA Protein Assay Kit (Pierce, Rockford,
USA) according to manufacturer’s instructions.
Calcium deposition was quantified at day 21 by staining
separate wells with 0.5% Alizarin Red S (Chroma, Mu ¨nster,
Germany). After washing the calcium-bound dye was extracted by
10% hexadecetylpyridinium-chloride-monohydrate (CPC) (Sigma,
Deisenhofen, Germany) and quantified at an OD of 570 nm. The
results were standardized to whole protein content as described
before.
Induction of Adipogenesis
MSC from passage 3 were harvested with trypsin/EDTA and
18,420 MSC/cm
2 (35,000 cells per well) were seeded in
adipogenic induction medium consisting of DMEM high glucose
(Gibco, Invitrogen, Karlsruhe, Germany), 10% FCS (Biochrom,
Berlin, Germany), 1 mm dexamethasone, 0.2 mM indomethacine,
0.5 mM isobutyl methylxanthine (all Sigma, Deisenhofen, Ger-
many), 0.01 mg/ml insulin (Sanofi-Aventis, Frankfurt, Germany)
Donor Age and Mesenchymal Stem Cells
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e22980and 100 units/ml penicillin, 100 mg/ml streptomycin (Biochrom,
Berlin, Germany).
At day 21 adipogenesis was quantified by fixing the cells with
4% paraformaldehyde and staining with 0.3% Oil Red O solution
(Chroma, Mu ¨nster, Germany). The dye was re-extracted by 60%
isopropanol and the optical density was measured at 490 nm.
Induction of Chondrogenesis
MSC from passage 3 were harvested with trypsin/EDTA and
pellets consisting of 5610
5 cells were formed by centrifugation.
Chondrogenic induction medium consisted of DMEM high
glucose (Gibco, Invitrogen, Karlsruhe, Germany) supplemented
with 0.1 mM dexamethasone, 0.17 mM ascorbic acid 2-phosphate,
5 mg/ml transferrin, 5 ng/ml selenous acid, 1 mM sodium
pyruvate, 0.35 mM proline, 1.25 mg/ml BSA, 100 units/ml
penicillin, 100 mg/ml streptomycin (Biochrom, Berlin, Germany),
5 mg/ml insulin (Sanofi-Aventis, Frankfurt, Germany) and 10 ng/
ml TGF-b1 (Peprotech, Hamburg, Germany). Pellets were
cultured for 6 weeks in chondrogenic induction medium and
medium was changed three times the weeks.
Histology. Pellets were fixed in 4% paraformaldehyde for 2 h
and staining procedures were performed using standard protocols.
Sections (5 mm) were stained with 1% Alcian blue (Chroma,
Mu ¨nster, Germany) for proteoglycans. Immunohistological
staining was performed as described previously (Winter et al.
2003). Sections were pretreated with 2 mg/ml hyaluronidase
(Merck, Darmstadt, Germany) and 1 mg/ml pronase (Roche
Diagnostics, Penzberg, Germany). PBS containing 5% bovine
serum albumin (BSA) was used to block non-specific background.
Sections were incubated overnight at 4uC with a monoclonal
mouse anti-human collagen type I or II antibody (clones I-8H5
and II-4C11, ICN Biomedicals, Aurora, Ohio, USA) in PBS
containing 1% BSA. Reactivity was detected using biotinylated
goat anti-mouse secondary antibody (1:500; 30 minutes, RT;
Dianova, Hamburg, Germany), streptavidin-alkaline phosphatase
(Dako, 30 minutes, 20uC) and fast red (Sigma-Aldrich,
Deisenhofen, Germany).
To evaluate the collagen type II positive area related to the
whole pellet, histomorphometrical analysis was performed by
AxioVision 3.0 software (Zeiss, Jena, Germany).
Quantification of proteoglycan content. Pellets (2 per
donor, n=56) were washed with PBS and fixed with 100 ml
methanol at 220uC. After washing, pellets were incubated with
0.5% Alcian blue solution (Chroma, Muenster, Germany) in 1 M
HCl over night. Pellets were then washed extensively with distilled
water and Alcian blue was extracted by 200 ml of 6 M guanidine
hydrochloride for 5 hours. The optical density of the extracted dye
was measured at 650 nm.
Collagen type II extraction and ELISA. Pellets (2 per
donor, n=56) were digested with pepsin solution (2.5 mg pepsin/
ml) (Sigma, Deisenhofen, Germany) for at least 16 hours. Digest
solution was neutralized with 1 M Tris Base (Roth, Karlsruhe,
Germany), 4.5 M NaCl (Roth, Karlsruhe, Germany) were added
and the solution was rotated over night at 4uC. After
centrifugation, the supernatant was discarded, pellets were
resuspended in 400 ml precipitation-buffer (0.1 M Tris Base,
0.4 M NaCl) and the collagens precipitated for 4 hours at
220uC with ethanol. After centrifugation, the supernatant was
discarded and the pellets were resuspended in lysis buffer (50 mM
Tris, 150 mM NaCl, 1% Triton X-100). Collagen type II content
was measured by Native type II collagen detection ELISA
(Chondrex, Redmond, USA) according to manufacturer’s
instructions.
RNA isolation and quantitative real time PCR
Total RNA was isolated from 0.3–2 Mio undifferentiated MSC
of passage 3 or 4 and cells after 12 days of osteogenic induction or
21 days of adipogenic induction using guanidinium thiocyanate/
phenol extraction (peqGOLD Trifast; Peqlab, Erlangen, Germany).
Polyadenylated mRNA was isolated from total RNA using oligo
d(T) coupled magnetic beads (Dynabeads, Dynal, Invitrogen
GmbH, Karlsruhe, Germany) according to the manufacturer’s
instruction. 20 ng of mRNA were subjected to first strand cDNA
synthesis using reverse transcriptase (OmniscriptH, Qiagen, Hilden,
Germany) and oligo-d(T) primers. Expression levels of individual
genes were analyzed by quantitative PCR using LightCycler
TM
technology (Roche Diagnostics, Penzberg, Germany). First strand
cDNA was diluted 1:5 and 2 ml were subjected to quantitative real
time PCR using the following gene-specific forward and reverse
primers: GAPDH: GGGAAGCTTGTCATCAATGG, CAGAG-
GGGGCAGAGATGAT; IBSP: CAGGGCAGTAGTGACTCA-
TCC, TCGATTCTTCATTGTTTTCTCCT; PPARG: TGA-
CAGGAAAGACAACAGACAAAT, GGGTGATGTGTTTGA-
ACTTGATT.
Specificity of the PCR products was confirmed by melting curve
analysis and agarose gel electrophoresis of PCR products. The
number of cDNA copies was correlated with the apparent
threshold cycle (CT). Building the difference between CT of the
gene of interest and CT of GAPDH from one sample gives delta-
CT values which can be expressed as percentage of GAPDH.
Statistical analysis
Experiments were conducted for 23–28 donors and each
parameter was assessed in duplicate for each donor. The mean
value of duplicates (n=23–28) were used for statistical analysis.
Correlations were evaluated with Spearman-Rho Test. The
comparison of gene expression regulation before and after
differentiation induction and differences between male and female
were evaluated by Mann-Whitney-U Test. p,0.05 was considered
significant.
Results
CFU-F-frequency and donor age
MNC from 25 bone marrow aspirates were seeded under
standardized conditions and although four isolates failed to
produce CFU-F with more than 30 cells at day 7, they nevertheless
gave an expandable MSC population with typical spindle-shaped
cells (Fig. 1A) which were positive for established surface markers
(data not shown). CFU-F numbers were highly donor-dependent
and ranged from 0–80 CFU-F per 12.5610
6 MNC. There was no
correlation between age and frequency of expandable MSC per
MNC fraction (Fig. 1B) and harvest site and gender also had no
apparent influence on MSC frequency.
Reduced growth activation with age
After seeding of 192 wells at a statistical density of 1 cell per well
for each donor (n=25) 0 to 22 expandable clones were obtained at
day 14 of culture. A significant negative correlation of SSCE with
donor age was evident (Fig. 2A) while no gender differences were
observed.
During further expansion of the non-clonal MSC populations
up to passage 4, the mean generation time, defined as the time
needed for one population doubling, increased from P0 to P4
independent of age groups (Table 1). A positive correlation
between donor age and generation time (Fig. 2B, C) was evident at
passages 2 (R
2=0.477, p=0.01) and 3 (R
2=0.669, p,0.001).
Four of ten donors above 60 years had a mean generation time at
Donor Age and Mesenchymal Stem Cells
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group, a phenomenon which did not correlate with age-related
pathologies like osteoarthritis, hypertension or diabetes, respec-
tively (data not shown). Again, no effect of gender was detected.
Taken together, we recorded an inferior average reactivation from
dormancy and slower initial growth rate for MSC from older
donors.
In vitro differentiation capacity was independent of
donor age
Although adipogenic differentiation measured by Oil Red O
staining varied between donors (Fig. 3A) quantification of
extracted Oil Red O (n=23 donors) revealed no correlation with
donor age (Fig. 3B). A weak trend to more lipid deposition with
younger age was not reflected by gene expression analysis of the
adipogenic marker Peroxisome proliferator-activated receptor
gamma (PPARG) in cells from the five youngest and five oldest
donors of the study (Fig. 3G). After 3 weeks of osteogenesis, all
MSC populations had deposited a mineralized matrix according to
Alizarin Red staining and quantification of mineralization showed
no correlation with donor age (Fig. 3C, D). ALP activity of cell
lysates was highly variable between donors and showed no
correlation with age (Fig. 3E). Gene expression of the osteogenic
marker Integrin-binding sialoprotein (IBSP) was tested in differ-
entiated MSC relative to undifferentiated control MSC for the five
youngest and five oldest donors of the study. IBSP up-regulation
was evident in both groups with no significant differences obtained
with age (Fig. 3F). There was no gender influence neither on
osteogenic nor on adipogenic differentiation.
After six weeks of chondrogenic induction in spheroid cultures,
donor variability was striking. Independent of age groups, the
histological staining for collagen type II ranged from the full
spheroid, except a small rim at the surface, to negative (Fig. 4A).
For inferior MSC populations, the staining differed sometimes
Figure 1. Number of Colony-forming units per mononuclear cell fraction of bone marrow aspirates. Seven days after initial seeding of
5610
5 mononuclear cells (MNC) per cm
2, obtained spots of mesenchymal stem cells (MSC) were counted as one CFU-F (A) if the cluster consisted of
more than 30 cells. (B) No correlation was obvious between the number of CFU-F and donor age. Correlation was calculated by Spearman-Rho Test.
doi:10.1371/journal.pone.0022980.g001
Figure 2. Single cell cloning efficiency at passage 0 and generation time at passage 2 and 3 correlate with donor age. (A) Clonal
expandability of minimally expanded MSC was evaluated by single cell cloning for MSC from 25 donors. Fourteen days after seeding of statistically
one single cell per well into two 96-well plates, wells containing .30 cells were counted as single cell clones. The clonal expandability decreased
significantly with increasing donor age. (B,C) Non-clonal MSC populations were expanded and generation time, specified as the time needed for one
population doubling, was recorded. Proliferation rate of MSC from passage 2 (B) and passage 3 (C) showed a significant correlation with donor age.
Correlation was calculated by Spearman-Rho Test and p,0.05 was considered as statistically significant.
doi:10.1371/journal.pone.0022980.g002
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histomorphometric analysis of the area of collagen type II staining
referred to the whole section reflected no correlation with donor
age. To our knowledge this is the first study in the context of
ageing providing quantitative data on collagen type II protein
deposition as marker for chondrogenic differentiation. In line with
histology, there was no correlation of collagen type II deposition
with donor age and a trend to inferior results at older age did not
reach significance (Fig. 4B). In parallel the proteoglycan content of
pellets revealed no age correlation (Fig. 4C) and both parameters
showed no gender differences (Fig. 4D) for chondrogenesis. Thus,
overall, in vitro lineage choice of MSC was unaltered with age.
Differentiation capacity - a correlate of generation time
Wenextdetermined whether the proliferation statusofthe MSCat
initiation of in vitro differentiation (here passage 3) may have
influenced differentiationoutcome. Indeed, weobserved animproved
differentiation capacity for osteogenesis (ALP activity R
2=20.582,
p=0.001), adipogenesis (Oil Red O measurement R
2=20.443,
p=0.034) and chondrogenesis (proteoglycan content R
2=20.414,
p=0.029; collagen type II content R
2=20.62, p=0.0) the faster the
cells proliferated which all correlated negatively with generation time
(Fig. 5 A–D, see marked examples of Fig. 3A and 4A). Remarkably,
thisnegative correlation was maintained for ALP and generationtime
(R
2=20.488, p=0.016) as well as for collagen type II content and
generation time (R
2=20.515, p=0.01) when the four samples with
a generation time above 100 hours were removed. Overall this
suggested that the proliferation rate at start of in vitro induction
rather than donor age was a major determinant for the in vitro
differentiation capacity of MSC.
Positive correlation between osteogenesis and
chondrogenesis
Interestingly, most MSC with low ALP activation during
osteogenesis failed to undergo chondrogenesis. Indeed, osteogenic
and chondrogenic differentiation capacity of MSC showed a strong
positive correlation (R
2=0.707, p,0.001) for collagen type II and
ALP activity (Fig. 5E) and for proteoglycan content and ALP
activity (R
2=0.623, p,0.001; data not shown) reflecting the close
relation between these two lineages known from the early
development of bone. A positive trend between ALP activity and
Oil Red O staining (R
2=0.405, p=0.055) almost reached
significance (Fig. 5F), giving a clear indication that MSC
populations with strong adipogenesis are not weak in osteogenesis
and vice versa as this may be expected from the in vivo observation
that during lifetime the bone marrow is replaced by fat marrow.
Discussion
This study provides a comprehensive analysis of MSC from
bone marrow aspirates of donors between 5 and 80 years collected
in three age groups. For each donor population, eight distinct
parameters were recorded under standardized conditions includ-
ing MSC frequency in primary isolates, MSC re-activation from
dormancy into the cell cycle, and in vitro lineage choice. At
maintained frequency of MSC per bone marrow cell fraction,
ageing impaired the in vitro activation of cells to grow under single
cell conditions and hampered the initial speed of proliferation
which declined during further expansion.
Since growing MSC were retrieved even from very old donors,
the ability to isolate MSC is per se no limitation for therapeutic
use. Importantly, not all donor MSC formed CFU-F cell clusters
after primary seeding, and four isolates grew rather as dispersed
non-clustering cells from the beginning. These tended to be
derived from older donors (3/4 above 60 years of age) but were no
outliers regarding proliferation and differentiation capacity. MSC
from adipose tissue also do not form typical CFU-F indicating that
colony formation may be no general criterion for MSC. In
addition all of our MSC-populations expressed nestin, a marker
recently shown to identify MSC [34]. This expression was
independent on CFU-F formation capacity and passage number.
Since the number of CFU-F per ml bone marrow aspirate varies
with the surgical aspiration technique [35] which can hardly be
standardized for patients undergoing surgery for different
indications, CFU-F data from this and previous studies are highly
variable between donors, largely not comparable and usually
provide no correlation with age (Table 2). As demonstrated
recently [36], bone marrow aspirates furthermore contain only a
minority of the MSC present in vivo. In light of these new data,
although determined frequently, CFU-F numbers hardly allow
concluding about the number of MSC in bone marrow in vivo.
The maintenance of MSC numbers with age is, therefore, an
important question which still remains open and should better be
addressed either by labelling in vivo or after full extraction of all
MSC from trabecular bone [36].
Plastic adherent growth is one definition criterion for MSC and
most cells may have been coaxed back into the cell cycle after
dormancy in vivo [37]. This study is the first to address the
reactivation of MSC in single cell cloning experiments in a
quantitative manner in the context of ageing. We believe that
exposing minimally expanded MSC to such extreme conditions
like single cell cloning represents a severe stress situation for the
cell which could mimic stress situations like tissue damage in vivo.
Importantly only the autonomous activity of a single cell is
recorded with no help from non-adherent, adherent or migrating
bystander cells. This could allow estimating the robustness of cells
and the quality by which MSC are reactivated to grow. Our data
show a decline in the average number of growing clones with age
suggesting a reduced stress-resistance and/or activation of
dormant MSC to fast cell growth at older age which may provide
one explanation for delayed fracture healing or an increasing
prevalence of degenerative diseases at older age [3,38].
Data onclonalexpandabilityarecomplemented bya significantly
slower initial proliferation rate in non-clonal cultures. That cells
from older donors proliferate more slowly than MSC from younger
subjects is in line with several previous reports [15,22,24,25,29]
althoughsomestudies with a restricted age range [14] orlowsample
numbers for young individuals [19] recorded no change in
proliferation with donor age (Table 2). Four of ten donors above
60 years had a much higher generation time at passage 3 than the
remainder of this group raising the question why some of the old
Table 1. Generation time of MSC of the three donor age
groups at passage 1–4 with results show mean values 6
standard deviation.
Generation time [hours per population doubling]
Age group young middle old
Passage 1 23.363.9 30.9615.9 32.467.4
Passage 2 35.466.0 36.5610.6 54.1620.6#
Passage 3 37.966.4 42.5610.6 89.4644.1#
Passage 4 78.4619.0 94.0647.7 116.9655.8
#sig. different to young and middle old group, p,0.05.
doi:10.1371/journal.pone.0022980.t001
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induced with adipogenic or osteogenic induction medium for 21 days in monolayer. (A) Adipogenesis of good (donor a) and impaired MSC (donor b)
was detected by Oil Red O staining of the lipid vacuoles and (B) measured by extraction of bound Oil Red O dye. (C,D) Osteogenic in vitro potential
was evaluated by quantification of mineral deposition by dye extraction after Alizarin Red staining. (E) Alkaline phosphatase activity of cell lysates was
determined using the pNP (para-Nitrophenylphosphate) substrate. No significant correlation of age and differentiation capacity was observed.
Correlation was calculated by Spearman-Rho Test. (F) Gene expression of the osteogenic marker Integrin-binding sialoprotein (IBSP) and (G) the
adipogenic marker Peroxisome proliferator-activated receptor gamma (PPARG) both normalized to the housekeeping gene GAPDH. Data are given as
x-fold regulation compared to undifferentiated control MSC of the same donors. Five of the youngest and the oldest donors of the whole collective
were used for analysis in RT-PCR. No difference for both markers was observed between the two age groups (Mann-Whitney-U-Test).
doi:10.1371/journal.pone.0022980.g003
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age-patients suffered from osteoarthritis and most of them suffered
from hypertension and diabetes these age-related pathologies could
not explain this phenomenon and further studies are needed to
answer this question in a larger cohort. Altogether, our data in
context with the current literature support an impaired in vitro
replicative function of MSC with advanced age. Proliferation rate
may have strong implications for therapeutic potency of MSC since
donor cells with generation time below a certain threshold level
were unable to form ectopic bone in a recent study [39]. When we,
however, adapted culture conditions for MSC to methods used for
expansion of embryonic stem cells we were able to accelerate
proliferation and to restore the in vivo bone formation of inferior
MSC. Thus, in principle, knowledge is available to overcome
activation and proliferation limitations of inferior MSC found here
predominantly for older donors in order to rescue such cells for
transplantation purposes where necessary.
One main finding of the present study was that differentiation
capacity into the adipogenic, osteogenic and chondrogenic lineage
was unaltered with age but showed a strong correlation to the
proliferation status of MSC at start of induction. Thus, cell
anabolism at shift to differentiation conditions was a major
determinant of in vitro multilineage differentiation capacity.
Although many studies determined changes in proliferation of
MSC and their osteogenic differentiation capacity with age, none
of the previous authors attempted to correlate these two important
parameters with each other. In light of our results conflicting data
to existing literature concerning maintenance [18,20,21,25,26,30]
or decline [24,28,29] of osteogenic in vitro differentiation capacity
of MSC might be solved if proliferation rate at start of in vitro
induction would be implicated as a parameter in these studies.
Overall, strong osteogenesis according to ALP activation
correlated with strong chondrogenesis and a trend to better
adipogenesis, thus providing no evidence for an altered lineage
Figure 4. No correlation of chondrogenic differentiation with donor age and gender. 5610
5 MSC were subjected to six weeks of
chondrogenic induction in high density culture. From 6 parallel pellets per donor, 2 pellets were used for histological stainings, 2 pellets were
processed for quantification of glycosaminoglycan deposition and 2 pellets for quantification of collagen type II deposition. (A) Immunohistochemical
staining for collagen type II was used to confirm chondrogenic differentiation and the chondrocyte-like morphology of the cells. Staining varied from
full to negative depending on the donor with similar variability in all age groups (A, inset). (B) The collagen type II content determined after pepsin
digestion of pellets by ELISA revealed a weak trend of reduced chondrogenesis at older age. (C) Glycosaminoglycan deposition determined after
staining the pellets with Alcian blue dye, washing and extracting the dye revealed a trend of reduced chondrogenesis at older age. (D) Collagen type
II deposition in pellets from female and male donors showed no significant differences. Correlation was calculated by Spearman-Rho Test, group
comparison by Mann-Whitney-U Test.
doi:10.1371/journal.pone.0022980.g004
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e22980Figure 5. Correlation of proliferation rate and differentiation capacity. (A) Osteogenic and (B) adipogenic differentiation of MSC (passage 3)
were induced for 21 days in monolayer. (A) ALP enzyme activity and (B) amount of extracted Oil Red O dye were plotted against generation time of
the expanded cells at start of differentiation. (C,D) Proteoglycan and collagen type II deposition of high density pellets were plotted against
generation time of the expanded cells at start of differentiation. All four differentiation parameters showed a significant negative correlation with
generation time suggesting a reduced differentiation capacity of more slowly growing cells. (E) Chondrogenic differentiation capacity (collagen type
II deposition) revealed a strong positive correlation with osteogenic differentiation capacity (ALP activity). (F) Additionally a trend for better
adipogenesis (Oil Red O staining) at enhanced osteogenesis (ALP actitivity) almost reached significance. Correlation was calculated by Spearman-Rho
Test and p,0.05 was considered as statistically significant. % donor a in Fig. 3A, q donor b in Fig. 3A, e donor c in Fig. 4A, n donor e in Fig. 4A.
doi:10.1371/journal.pone.0022980.g005
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regulation of mRNA expression levels (Fig. 3F, G), we saw no
inverse correlation between osteogenesis (ALP activity) and
adipogenesis (Oil red deposition) as this may be suspected from
a reduced bone mass and increased fat content of bones at
advanced age in vivo.
Gender effects were reported in two previous studies describing
an age effect for women but not men regarding osteogenic
differentiation capacity (Table 2) [16,17]. While Leskela ¨ et al. [17]
suggested an increasing osteogenicity in women with age,
Muschler et al. [16] reported the opposite, a decrease of ALP
activation. For chondrogenesis, in contrast, one study observed no
effect for women, while MSC from male donors showed a
decreasing chondrogenic differentiation capacity with age [27].
Interestingly, we recorded a statistically significant age difference
between men and women in the corresponding study with younger
donors being predominantly male while older donors were
predominantly female. In view of our own data and in context
with the available literature (Table 2) it is therefore highly doubtful
that any gender-specific ageing effects exist for osteogenic and
chondrogenic MSC lineage commitment especially since studies
on osteoporotic donors see no changes versus age-matched healthy
controls [21,26].
In sum this study identified a deficit in activation from
dormancy and early replicative function of MSC suggesting that
it may be more demanding to mobilize MSC to fast cell growth at
advanced age. Since high proliferation came along with high
multilineage capacity, the proliferation status of expanded MSC
rather than donor age may provide an argument to restrict MSC-
based therapies to certain individuals. Since knowledge is available
to overcome limitations in activation and proliferation of inferior
MSC [39], it should be possible to produce promising cell
populations for transplantation purposes independent of donor
age.
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